BPC 157 and ipamorelin under FDA scrutiny Alex Keoskey posted on the topic LinkedIn This is one of the biggest peptide regulatory shifts in years. And it's just getting started. The FDA has taken its first step toward reversing its 2023 stance, removing 12 peptides from BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with GHK Cu, BPC 157, TB 500 Wolverine Stack Dosage Guide Preferred Regen ATL